OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
PRPO
Precipio, Inc.
There isn't enough reported data to score PRPO yet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
PRPO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Healthy | |
| Strong |
PRPO's revenue, cash flow and balance sheet are currently healthy, but its profitability is under pressure.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
PRPO PE Valuation
PRPO has no meaningful PE right now: it lost money over the past year.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
PRPO Forward outlook
There aren't enough analyst estimates for PRPO to show an outlook.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over PRPO on earnings quality, reporting a profit while its opponent remains loss making.
PRPO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.57 | +$0.24 |
| Q2 2026 | -$0.62 | +$0.56 |
| Q1 2026 | -$0.45 | +$1.61 |
| Q4 2025 | -$0.23 | +$2.70 |
| Q3 2025 | -$0.81 | +$1.24 |
| Q2 2025 | -$1.18 | +$1.49 |
| Q1 2025 | -$2.06 | +$1.58 |
| Q4 2024 | -$2.93 | +$1.85 |
PRPO is still losing money, but far less than before: $0.57 per share over the past year, against $52.60 at its worst in early 2020.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over PRPO on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over PRPO on profitability, with a higher operating margin.
PRPO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $7.3M | +8.3% |
| Q2 2026 | $7M | +24% |
| Q1 2026 | $6.7M | +36% |
| Q4 2025 | $6.7M | +23% |
| Q3 2025 | $6.8M | +30% |
| Q2 2025 | $5.7M | +27% |
| Q1 2025 | $4.9M | +44% |
| Q4 2024 | $5.5M | +26% |
PRPO's revenue has grown year over year for 15 quarters in a row: $7M last quarter, up 8.3% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 0% | +0.9 points |
| Q2 2026 | -8.5% | +6 points |
| Q1 2026 | -21% | -3.9 points |
| Q4 2025 | 8.1% | +14 points |
| Q3 2025 | -0.9% | +11 points |
| Q2 2025 | -15% | +13 points |
| Q1 2025 | -17% | +43 points |
| Q4 2024 | -6.2% | +14 points |
PRPO's operating margin was 0% last quarter, up 0.9 points from the same quarter a year ago, near the top of its range since 2019.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
PRPO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $554K | +$598K |
| Q2 2026 | $528K | +80% |
| Q1 2026 | $14K | +$196K |
| Q4 2025 | $291K | -44% |
| Q3 2025 | -$44K | +$24K |
| Q4 2024 | $521K | +702% |
| Q3 2024 | -$68K | +$851K |
| Q4 2023 | $65K | +$1.6M |
PRPO has the edge over OSCR on cash flow, with more consistent year-over-year improvement.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
PRPO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +3.5K shares |
| 1 year | +9.4% | +153K shares |
| 3 years | +28% | +396K shares |
| 5 years | +58% | +655K shares |
| Available history | +529% | +1.5M shares |
PRPO has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
PRPO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2025 | -59.9x | Net Cash |
PRPO has more cash than debt.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
PRPO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 49.6 | Neutral |
| Stochastic | 14.4 | Oversold |
PRPO's weekly RSI is 50 (neutral) and its Stochastic is 14 (oversold).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
PRPO PE vs Healthcare Sector
PRPO has no meaningful PE right now: it lost money over the past year.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over PRPO on trend strength, trading above more of its moving averages.
PRPO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $21.4 | 8.6% above |
| 20 week MA | $23.9 | 2.8% below |
| 50 week MA | $24.6 | 5.3% below |
| 100 week MA | $18.2 | 27% above |
| 200 week MA | $13.1 | 78% above |
PRPO's trend is mixed: it's above three of its five weekly moving averages, and 78% above its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over PRPO on returns for 2026, with the stronger performance.
PRPO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $40.8 | $41.8 | +2.5% |
| 2021 | $41.8 | $35.6 | -15% |
| 2022 | $35.6 | $11.0 | -69% |
| 2023 | $11.0 | $6.50 | -41% |
| 2024 | $6.50 | $5.51 | -15% |
| 2025 | $5.51 | $23.8 | +331% |
| 2026 YTD | $23.8 | $23.3 | -2.1% |
PRPO's yearly returns have swung widely, from +331% in 2025 to −69% in 2022. It's down 2.1% so far in 2026.